14-day Premium Trial Subscription Sign Up For FreeGet Free
Nasdaq - Total Crash or Bounce-Up? Click To Watch.

$6.00 (1.18%)

Volume: 273.633k

Closed: Sep 30, 2022

Hollow Logo Score: 2.807

Capricor Therapeutics Stock Forecast

$6.00 (1.18%)

Volume: 273.633k

Closed: Sep 30, 2022

Score Hollow Logo 2.807

Capricor Therapeutics Company Profile

10865 Road to the Cure, Suite 150

San Diego CA 92121

310 358 3200

www.capricor.com

Industry: Biotechnology

Sector: Healthcare

Capricor Therapeutics

Description

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

Hot Stocks To Watch:

IMPROVE YOUR TRADING GAME WITH A GOLDEN STAR

From 26 676 stocks, only a few dozen will trigger such a signal!

About Capricor Therapeutics

Capricor Therapeutics Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Ph... CAPR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT